Why Is ClinicalTrials.gov Still Struggling?

With no clear benefits to researchers, a frustrating user experience, and no penalties for non-compliance, ClinicalTrials.gov is becoming increasingly irrelevant to clinical researchers and the world at large with each passing day. What does this mean for public access to research results? Is an obligation to patients putting themselves at risk in trials being breached? Why has it failed to live up to its potential?

The Preemptive Publisher

In a business environment characterized by risks, upstart innovations, and even contempt for the law, publishers have to ward off threats the old-fashioned way, by out-innovating their rivals and preempting new services.